Full Press Release Details
Pharmaceuticals Reports THIRD Quarter 2021 Financial Results
PROVIDES BUSINESS UPDATE
- Second Phase 1/2 Study of Fadraciclib
Now Enrolling Patients in Leukemia -
- Cash Runway to Early 2023 -
- Conference Call Scheduled November
10, 2021 at 4:30 p.m. ET -
Berkeley Heights, NJ, November
10, 2021 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical
company developing innovative medicines based on cancer cell biology, today reported its financial results for the third quarter 2021.
The quarter's business highlights include an update on the Company's progress with fadraciclib and CYC140, Cyclacel's novel
CDK2/9 and PLK1 inhibitors, respectively.
"The Cyclacel team continued
to execute on our plan during the quarter with the opening of two Phase 1/2 studies for oral fadraciclib and filing an IND for a Phase
1/2 study of our oral PLK1 inhibitor, CYC140," said Spiro Rombotis, President and Chief Executive Officer. "We have now enrolled
a total of six patients across two dosing levels in our fadraciclib study in solid tumors and have started the first dose level in the
fadraciclib study in leukemia. We are pleased with the strong investigator interest in our studies as we build a global network of participating
institutions for our clinical studies and preclinical collaborations.
We are also looking forward
to the near future with the planned initiation of two registration-enabling Phase 1/2 studies of CYC140 in patients with solid tumors
and leukemias and reporting initial data for fadraciclib in solid tumors. We remain diligently focused on bringing innovative treatment
options to cancer patients with unmet medical needs and realizing the promise of our pipeline."
Key Corporate Highlights
Oral fadraciclib program
| Six patients with advanced solid tumors treated in the first two dosing levels of 065-101, Phase 1/2, registration-directed study | ||
| Two additional internationally-recognized cancer treatment centers added to 065-101 selected for their expertise with tumor types of interest; for a total of four sites | ||
| First patient dosed in the 065-102, Phase 1/2, registration-directed study in patients with leukemia | ||
| Multiple preclinical studies in progress which will inform fadraciclib's clinical development |
| Filed with FDA an IND for a streamlined, registration-directed, Phase 1/2 study of orally-available CYC140 in solid tumors | ||
| Initial data in preclinical models show that KRAS mutant cancers are sensitive to oral CYC140 inhibition | ||
| Preclinical collaborative studies ongoing to support selection of histologies to be included in the Phase 1/2 study |
200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922,
USA Tel +1 908 517 7330 Fax +1 866 271 3466
Key Near-Term Business Objectives
| FDA clearance of IND filing and initiation of oral CYC140 Phase 1/2 advanced solid tumor study | ||
| Initial data from first part of 065-101 study with oral fadraciclib in advanced solid tumors | ||
| First patient to be dosed with oral CYC140 in Phase 1/2 leukemia study | ||
| Initial data from first part of 065-102 study with oral fadraciclib in leukemia |
Financial Highlights
As of September 30, 2021, cash and cash equivalents totaled $40.2
million, compared to $43.6 million as of June 30, 2021. The decrease of $3.4 million was primarily due to $6.3 million net cash used
in operating activities, offset by $2.9 million cash provided by financing activities. The Company estimates that available cash resources
will fund currently-planned programs through early 2023.
Research and development (R&D) expenses were $4.2 million for
the three months ended September 30, 2021 as compared to $1.1 million for the same period in 2020. R&D expenses relating to fadraciclib
increased by approximately $2.5 million for the three months ended September 30, 2021 due to clinical supply manufacturing and opening
of clinical trial sites for the evaluation of fadraciclib in Phase 1/2 studies. Additionally, R&D expenses related to CYC140 increased
$0.5 million for the quarter as preclinical evaluation and clinical trial supply manufacturing of CYC140 progressed.
General and administrative expenses for the three months ended September
30, 2021 were $1.8 million, compared to $1.5 million for the same period of the previous year due to increased legal, professional and
recruitment costs relating to expansion of the clinical team.
United Kingdom research & development tax credits were $1.0 million
for the three months ended September 30, 2021, as compared to $0.3 million for the same period in 2020 due to the increase in R&D
Net loss for the three months ended September 30, 2021 was $5.0 million,
compared to $2.3 million for the same period in 2020.
Conference call information:
Conference ID: CYCCQ321
US call: (877) 876-9173/ international call:
Replay: US: (800) 938-2795 / international archive:
Code for live and replay conference call is CYCCQ321 Webcast link.
and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical
company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional
regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients
with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business
based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
Forward-looking Statements
This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding,
among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future
clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors
that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research
and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling,
Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital
requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization
of product candidates. You are urged to consider statements that include the words "may," "will," "would,"
"could," "should," "believes," "estimates," "projects," "potential," "expects,"
"plans," "anticipates," "intends," "continues," "forecast," "designed," "goal,"
or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the
risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings
we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking
statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether
as a result of new information, future events or otherwise.
Copyright 2021 Cyclacel Pharmaceuticals,
CYCLACEL PHARMACEUTICALS,
CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)
(In $000s, except share
and per share amounts)
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2020 | 2021 | |||||||
| Revenues: | ||||||||
| Total revenues | - | - | ||||||
| Operating expenses: | ||||||||
| Research and development | 1,075 | 4,217 | ||||||
| General and administrative | 1,497 | 1,781 | ||||||
| Total operating expenses | 2,572 | 5,998 | ||||||
| Operating loss | (2,572 | ) | (5,998 | ) | ||||
| Other income (expense): | ||||||||
| Foreign exchange gains (losses) | (25 | ) | 9 | |||||
| Interest income | 4 | 4 | ||||||
| Other income, net | 56 | - | ||||||
| Total other income (expense), net | 35 | 13 | ||||||
| Loss before taxes | (2,537 | ) | (5,985 | ) | ||||
| Income tax benefit | 281 | 998 | ||||||
| Net loss | (2,256 | ) | (4,987 | ) | ||||
| Dividend on convertible exchangeable preferred shares | (50 | ) | (50 | ) | ||||
| Beneficial conversion feature of Series B preferred stock | - | - | ||||||
| Net loss applicable to common shareholders | $ | (2,306 | ) | $ | (5,037 | ) | ||
| Basic and diluted earnings per common share: | ||||||||
| Net loss per share - basic and diluted | $ | (0.47 | ) | $ | (0.54 | ) | ||
| Weighted average common shares outstanding | 4,863,984 | 9,368,056 |
SOURCE: Cyclacel Pharmaceuticals, Inc.
CYCLACEL PHARMACEUTICALS,
CONSOLIDATED BALANCE
(In $000s, except share,
per share, and liquidation preference amounts)
| December 31, | September 30, | |||||||
| 2020 | 2021 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 33,406 | $ | 40,219 | ||||
| Prepaid expenses and other current assets | 2,063 | 3,156 | ||||||
| Total current assets | 35,469 | 43,375 | ||||||
| Property and equipment, net | 106 | 71 | ||||||
| Right-of-use lease asset | 1,227 | 44 | ||||||
| Non-current deposits | - | 1,509 | ||||||
| Total assets | $ | 36,802 | $ | 44,999 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 514 | $ | 1,515 | ||||
| Accrued and other current liabilities | 1,972 | 2,076 | ||||||
| Total current liabilities | 2,486 | 3,591 | ||||||
| Lease liability | 1,057 | 44 | ||||||
| Total liabilities | 3,543 | 3,635 | ||||||
| Stockholders' equity | 33,259 | 41,364 | ||||||
| Total liabilities and stockholders' equity | $ | 36,802 | $ | 44,999 |
SOURCE: Cyclacel Pharmaceuticals, Inc.